| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/IJC.21444 |
| P698 | PubMed publication ID | 16114017 |
| P50 | author | Ka Fai To | Q99551275 |
| P2093 | author name string | Kwok-Wai Lo | |
| Angela Bik-Yu Hui | |||
| Cleo Nga-Yee Lam | |||
| Yvonne Yan-Yan Or | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 3 | |
| P304 | page(s) | 1065-1067 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | PIK3CA mutations in nasopharyngeal carcinoma. | |
| P478 | volume | 118 |
| Q39352296 | Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. |
| Q100945769 | Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma |
| Q91991154 | Correlation between important genes of mTOR pathway (PI3K and KIT) in Iranian women with sporadic breast cancer |
| Q27332333 | Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma |
| Q39441281 | EBV-related lymphomas: new approaches to treatment |
| Q34050917 | Epigenetic inactivation of inositol polyphosphate 4-phosphatase B (INPP4B), a regulator of PI3K/AKT signaling pathway in EBV-associated nasopharyngeal carcinoma |
| Q40046633 | Epstein-Barr virus infection and nasopharyngeal carcinoma |
| Q55036376 | Increased Expression of Phosphatidylinositol 3-Kinase p110α and Gene Amplification of PIK3CA in Nasopharyngeal Carcinoma. |
| Q38690528 | Investigational drugs for nasopharyngeal carcinoma |
| Q38385856 | Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). |
| Q37474182 | Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer |
| Q37982126 | Novel systemic therapeutic for nasopharyngeal carcinoma. |
| Q28284802 | Oncogenic mutations of PIK3CA in human cancers |
| Q82644957 | PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events |
| Q45226982 | PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival |
| Q33942405 | PIK3CA mutations in mucinous cystic neoplasms of the pancreas |
| Q40809231 | Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC). |
| Q39246432 | Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines |
| Q47155578 | Prognostic Value of Molecular Markers and Implication for Molecular Targeted Therapies in Nasopharyngeal Carcinoma: An Update in an Era of New Targeted Molecules Development |
| Q37687527 | Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers. |
| Q92062685 | Targeted sequencing of cancer-related genes in nasopharyngeal carcinoma identifies mutations in the TGF-β pathway |
| Q30365726 | The determinants of head and neck cancer: Unmasking the PI3K pathway mutations |
| Q38982367 | The genomic landscape of nasopharyngeal carcinoma |
Search more.